Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
30–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and Females 30-80 years old
Use of highly effective methods of contraception during study in women of childbearing potential
Outpatients
Clinical diagnosis of Parkinson's Disease according to UK Parkinson's Disease Society Brain Bank Clinical Diagnosis criteria
Score of \>/= 2 on UPDRS items 32 and 33
Dyskinesias for at least 3 months before baseline
On stable treatment regimen with L-dopa and other anti-parkinsonian treatment for 4 weeks prior to baseline
Demonstrate capacity to complete accurate diary ratings
Patients who have a primary caregiver willing to assess the condition of the patient throughout the study in accordance with protocol requirements
Group 2 only: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study
You may not be if
Atypical/secondary form of Parkinson's disease
History of surgical treatment of PD, including deep brain stimulation
A score of 5 in the "ON"- state on the Modified Hoehn and Yahr scale
Advanced, severe, or unstable disease other than PD
Evidence of dementia
Treatment with certain prohibited medications
Amantadine within 2 weeks prior to BL1 visit (applies to Group 1 only)
Clareo Health | Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
